VGXI has long been recognized for its exceptional quality in DNA products and services, and under Mr. Whitmore’s leadership, the company aims to fuel rapid growth, consolidate its global brand positioning, and expand its client base.

CONROE, Texas (PRWEB)
May 31, 2023

VGXI Inc., a distinguished Texas-based Contract Development and Manufacturing Organization (CDMO) specializing in the production of plasmid DNA and RNA biopharmaceuticals, is pleased to announce the appointment of Mr. Jeff Whitmore as Chief Commercial Officer (CCO). With over 25 years of experience in the biotechnology industry, Whitmore brings valuable expertise to VGXI’s corporate team, having previously served as CCO for Genezen and VP of Commercial Operations at TriLink BioTechnologies.

In his role as CCO, Whitmore will drive the commercial team’s efforts to support VGXI’s newly opened headquarters and state-of-the-art production facility located at Deison Technology Park in Conroe, TX. The facility expansion is part of VGXI’s overall transition from a boutique manufacturing organization into a full-scale commercial operation, catering to the growing demands of the vaccine, immunotherapy, and cell and gene therapy industries. VGXI has long been recognized for its exceptional quality in DNA products and services, and under Mr. Whitmore’s leadership, the company aims to fuel rapid growth, consolidate its global brand positioning, and expand its client base.

“Jeff is a skillful strategist with a track record of success in product value positioning and leading transitional growth, as demonstrated during his time at TriLink,” said VGXI’s President and CEO, Young Park. “We are excited for him to join the VGXI team.”

This announcement follows the recent appointment of Mr. Jim Smith as Chief Accounting Officer, highlighting VGXI’s commitment to fostering rapid business expansion and the development of commercial services.

ABOUT VGXI, INC.

With over 20 years of experience VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and highly experienced development team. VGXI, Inc. is a GeneOne company. To learn more, visit https://www.vgxii.com.

ABOUT GENEONE LIFE SCIENCE

GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II). For more information, visit http://www.genels.com.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

Photo Credit: International Blue Crescent

“The situation in Türkiye remains a crisis for those impacted by the earthquakes,” said Nagulan Nesiah, Senior Program Officer, Disaster Resilience.

NEW YORK (PRWEB)
May 31, 2023

Episcopal Relief & Development is partnering with Diakonie Katastrophenhilfe (DKH) and International Blue Crescent (IBC) to provide food, shelter, supplies and mental health support to people in Türkiye affected by the earthquakes in early February 2023.

Close to 18 million people in Türkiye and Syria were impacted by the earthquakes, which killed over 55,000 people and injured almost 130,000. Before the quake, Türkiye hosted the largest number of refugees in the world, including 3.6 million Syrians. Currently, over four million people in Türkiye are living in tents or informal shelters near their damaged homes.

“The situation in Türkiye remains a crisis for those impacted by the earthquakes,” said Nagulan Nesiah, Senior Program Officer, Disaster Resilience. “We are actively engaging with our partners throughout the region to continue to assess peoples’ needs and provide support as necessary.”

With Episcopal Relief & Development’s support, DKH is responding to meet the needs of over 30,000 people in Türkiye by providing needs-based, dignified, safe and community-driven support. Their response will include providing shelter to 2,000 people, family hygiene kits for 12,000, clean water for 4,800, mental health services for 300 and staff care for 95.

Additionally, Episcopal Relief & Development is working with IBC to support 1,000 displaced people living in a camp in Özdere, Izmir, Türkiye. IBC will also provide hot meals, cleaning supplies and personal hygiene kits to those living in the camp, who range from infants to elderly people.

Please continue to pray for those who have been affected by the earthquake. Donations to the Türkiye-Syria Earthquake Response Fund will help the organization to continue to respond to communities impacted by this disaster.

ABOUT EPISCOPAL RELIEF & DEVELOPMENT

For over 80 years, Episcopal Relief & Development has been working together with supporters and partners for lasting change around the world. Each year the organization facilitates healthier, more fulfilling lives for more than 3 million people struggling with hunger, poverty, disaster and disease. Inspired by Jesus’ words in Matthew 25, Episcopal Relief & Development leverages the expertise and resources of Anglican and other partners to deliver measurable and sustainable change in three signature program areas: Women, Children and Climate.

Share article on social media or email:

Shelter Dog and Animal Control Officer

“We are at the tipping point of taking the country no-kill,” said Julie Castle, CEO, Best Friends Animal Society. “This critical mass of no-kill shelters shows that it’s possible to save every healthy and treatable pet in a shelter, and it’s sustainable.”

KANAB, Utah (PRWEB)
May 31, 2023

Best Friends Animal Society, a leading animal welfare organization working to end the killing of cats and dogs in shelters by 2025, released its annual data report today which gives the most accurate and comprehensive national overview of the number of dogs and cats that enter and exit shelters in a given year. The most noteworthy takeaway is the number of no-kill* shelters in the U.S. was at an all-time high at 57% in 2022. This is up from 24% in 2016 when Best Friends announced its goal to make America no-kill by 2025.

“We are at the tipping point of taking the country no-kill,” said Julie Castle, CEO, Best Friends Animal Society. “This critical mass of no-kill shelters shows that it’s possible to save every healthy and treatable pet in a shelter, and it’s sustainable. 93% of shelters that were no-kill in 2021 were able to maintain it the following year.”

The data also showed that the number of dogs and cats killed in U.S. shelters had a setback, with an increase to around 378,000. This was largely due to shelters experiencing higher intakes and lower adoptions. However, it also showed that nearly 60% of the increase came from just 1% of shelters, which were primarily large, municipal agencies. This means targeted programming proven to save more lives, including partnerships between no-kill and not yet no-kill shelters, as well as shelters and rescue groups, Best Friends staff embeds, cat and big-dog-focused initiatives, and advocacy work can help fix the problem.

Recent industry data revealed that dogs acquired from breeders and pet stores have been steadily increasing over the past few years. Dog adoptions stalled at just under 1 million last year, while intake was up by approximately 100,000 (the majority of which were strays, not returns). Compared to 2021 when cats were killed at twice the rate of dogs in shelters, there was a significant drop in the dog save rate in 2022 (83%, down from 87% in 2021). Fostering and adoption of dogs and cats is vital to get back on track to make shelters no-kill by 2025.

More statistics from the 2022 dataset:

• The number of pets that entered shelters nationally was 4.4 million, which is an increase of 1.6% over 2021.
• While dogs and cats entered shelters at about an equal rate, cats made up 55% of the killing, while dogs were 45%. Cats remain the most vulnerable in shelters, especially during “kitten season,” the summer months when cats reproduce and kittens flood shelters.
• The national save rate dropped slightly from 83.5% in 2021 to 81.4% in 2022. But shelter lifesaving is still trending in the right direction as the total number pets killed per year dropped by about 653K (-63.3%) since 2016.
• Five states make up 54% of the overall number of dogs and cats killed in 2022 (Texas, California, North Carolina, Florida, and Georgia).
• Vermont joined Delaware and New Hampshire as no-kill states, meaning that every shelter in each of those states was no-kill. Rhode Island, North Dakota, Maine and Montana were each on the cusp with a combined total of just over 300 dogs and cats to save to earn no-kill.

“We’ve made great progress and there is still momentum for our achievable goal, despite the small dip in lifesaving in 2022. 2025 is only two years away, so now is the time to support your local shelters. Together, let’s make every shelter and every community no-kill by 2025,” added Castle.

Individuals can help save lives by choosing to adopt from a shelter or rescue group instead of purchasing from a breeder or store, spay or neuter their pets, foster kittens or an adult dog, volunteer, donate, and advocate for proven lifesaving programming for pets.

About the data

For the past seven years, Best Friends has spearheaded a one-of-a-kind extensive data collection process that involves coordinated outreach to every shelter in America followed by additional research, data analysis, and technology development. The dataset is the most comprehensive on U.S. sheltered animals, and is based on data collected directly from shelters, state and local coalitions, government websites, and FOIA requests. From this, 95% of the animal intake in U.S. shelters is known, 5% is estimated. Best Friends has the most recently available annual data for 85% of shelters nationwide, nearly three times the amount of Shelter Animals Count and four years newer than that of the American Society for the Prevention of Cruelty to Animals.

*A 90 percent save rate is the nationally recognized benchmark to be considered “no-kill,” factoring that approximately 10 percent of pets who enter shelters have medical or behavioral circumstances that warrant humane euthanasia rather than killing for lack of space.

About Best Friends Animal Society

Best Friends Animal Society is a leading animal welfare organization working to end the killing of dogs and cats in America’s shelters by 2025. Founded in 1984, Best Friends is a pioneer in the no-kill movement and has helped reduce the number of animals killed in shelters from an estimated 17 million per year to around 378,000. Best Friends runs lifesaving programs across the country, as well as the nation’s largest no-kill animal sanctuary. Working collaboratively with a network of more than 4,200 animal welfare and shelter partners, and community members nationwide, Best Friends is working to Save Them All®. For more information, visit bestfriends.org.

Share article on social media or email:

CarolinasDentist, a North Carolina-based dental practice, has opened a new office serving Asheville led by Dr. Laura Johnson.

Our incredible team is so excited to open our CarolinasDentist office to serve Asheville and the surrounding community with dental care and smile transformations.

ASHEVILLE, N.C. (PRWEB)
May 31, 2023

CarolinasDentist, a leading dental care provider in North Carolina, is excited to announce the opening of its newest location serving Asheville. Located at 31 Long Shoals Road in Arden, N.C., the new CarolinasDentist location is headed by Dr. Laura Johnson and her husband, Dr. Sean Dekow. The practice will host a grand opening celebration on Monday, June 5, from 11 a.m. to 1 p.m. The event is open to the public.

As a homegrown North Carolina dental practice with a commitment to providing the highest quality of dental care to patients, CarolinasDentist is proud to expand its services to the Asheville community. The new location features state-of-the-art technology, modern amenities, and a team of highly skilled dental professionals dedicated to ensuring patient comfort and satisfaction.

“Our incredible team is so excited to open our CarolinasDentist office to serve Asheville and the surrounding community with dental care and smile transformations,” said Dr. Johnson, who has been with CarolinasDentist since 2016.

Dr. Johnson and Dr. Dekow bring many years of experience and expertise to the Asheville practice, offering a wide range of services that include: routine cleanings, fillings, root canals, cosmetic dentistry, and more. Patients can expect personalized care, attention to detail, and a focus on education and prevention to help maintain optimal oral health.

CarolinasDentist is now accepting new patients. To schedule an appointment, call (828) 998-0319 or visit carolinasdentist.com. The address is: 31 Long Shoals Rd., Arden, N.C, 28704.

CarolinasDentist is a North Carolina-based dental practice with 13 convenient locations across the state. We believe in “positively different dentistry” by offering a relaxing environment with high-quality dental care centered on making sure our patients’ needs are met. Patients benefit from convenient scheduling and a high standard of care from skilled dental professionals using modern technology. From cavity prevention to dramatic smile makeovers, patients think of CarolinasDentist as their trusted dental home. We’ll be there for you when your little one gets their first tooth, and we’ll be there for you thereafter for every stage of life.

Share article on social media or email:

Corey Fenoglio

“With his proven track record of success and innovative mindset, I am confident that Corey will contribute significantly to our growth as he heads up business development in the western part of the country.”– Spencer Young, MedReview CEO

NEW YORK (PRWEB)
May 31, 2023

MedReview, Inc., a leading provider of payment integrity services, is pleased to welcome Corey J. Fenoglio, RN, BSN, MHP, HCAFA, to head up business development in the western half of the US. Experienced in approaching sales from a consultative perspective, Fenoglio will educate and advise C-level payer executives and their teams on how MedReview’s payment integrity can best address their specific needs. He will apply his decades of experience in cultivating new business relationships and nurturing existing ones to continue MedReview on its current high-growth trajectory.

“We are very excited to welcome Corey to our team,” said MedReview Chief Executive Officer, Spencer Young. “His knowledge, expertise, and passion for healthcare make him an invaluable addition to our organization. With his proven track record of success and innovative mindset, I am confident that Corey will contribute significantly to our growth as he heads up business development in the western part of the country.”

Fenoglio’s broad background in sales management and business development both inside and outside the healthcare sphere will be integral to supporting MedReview’s growth strategy. He has experience with payment integrity, compliance, and value-based reimbursement. Fenoglio has also trained and worked as a registered nurse. He is adept in creating new relationships and revenue streams by combining business development skills with a consultative approach. In his roles as vice president of payer solutions at Optum and vice president of business development at CareCentrix, he consistently exceeded sales quotas.

Fenoglio’s most recent position was as vice president of payer strategies at Vital Data Technology. He advised health plans, government programs, and third-party administrators on best practices for data integration and automation. In this role, he drove marketing strategy, brand recognition, and thought leadership.

Fenoglio earned a bachelor of arts in finance from Midwestern State University in Texas and a bachelor of science in nursing, magna cum laude, from Baylor University. He has Managed Healthcare Professional and Health Care Anti-Fraud Associate designations and is a licensed nurse in Texas.

About MedReview

Headquartered in the financial district of New York City and serving all U.S. states and territories, MedReview has been a leading provider of payment integrity, utilization management and quality surveillance services for more than 40 years. A physician-led organization with a passion for ensuring that health care claims fairly represent the care provided, MedReview provides timely independent hospital billing audits and DRG clinical validation reviews on behalf of health plans, government agencies and Taft-Hartley organizations, saving millions of dollars for its clients each year.

Share article on social media or email:

It has been a privilege working with UR Medicine over the past three years on this project that truly revolutionizes how we think about the delivery of outpatient orthopaedic care.

MILWAUKEE (PRWEB)
May 31, 2023

Hammes Healthcare, a leading provider of consulting and project delivery services, is pleased to celebrate the opening of the UR Medicine Orthopaedics & Physical Performance Surgery Center in Henrietta, New York.

The first-of-its-kind orthopaedic ambulatory surgery center (ASC) is an adaptive reuse of the former Sears wing at The Marketplace Mall. The 150,000-square-foot ASC includes eight operating rooms and additional pre-and post-operative rooms to support the most complex orthopaedic surgical procedures in an ambulatory environment.

The opening of the ASC marks the completion of the first phase of the project. The second phase is a state-of-the-art motion and gait analysis lab, the CHAMPP (Center for Human Musculoskeletal Performance and Prevention) and a four-story tower comprised of exam rooms and imaging. Once completed in late 2023, the UR Medicine Orthopaedics & Physical Performance Center will be the largest and most comprehensive orthopaedic facility in the Northeastern United States.

“It has been a privilege working with UR Medicine over the past three years on this project that truly revolutionizes how we think about the delivery of outpatient orthopaedic care,” said Nancy Connolly, President of Hammes Healthcare. “We look forward to executing the final phase of the project in partnership with UR Medicine and exceptional project team members.”

About Hammes Healthcare

Hammes Healthcare is a national consulting firm that provides real estate and market strategy, facility planning, project management and development services to the healthcare industry. As a reflection of its commitment to the healthcare industry, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 25 consecutive years—including 20 years as No. 1—and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. https://www.hammes.com/

Share article on social media or email:

These findings reinforce that regular aerobic exercise is an important tool in asthma management.

MILWAUKEE (PRWEB)
May 31, 2023

Supervised high-intensity interval training could reduce the need for inhaled corticosteroids (ICS) in asthma patients who had not previously undergone this type of exercise, supporting exercise as a nonpharmacological component of asthma management. The finding comes from a new study published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), a journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Researchers in Denmark compared adults with persistent asthma across two groups. The control group maintained their regular lifestyle while the exercise group underwent six months of ongoing supervised high-intensity exercise three times a week. Every second month during the study, a clinical algorithm based on symptom control was utilized with both groups to make adjustments to ICS doses.

A total of 150 individuals participated in the study, with 102 in the exercise group and 48 in the control group. After six months, 63.1% of participants in the exercise group had reduced their ICS dose by 25% or more, compared to 50% in the control group. “What this means is we saw a 24% reduction in daily ICS dose in the exercise group compared to the control group,” said Anders Pitzner-Fabricius, MD, PhD, corresponding author for the study. “We already know physical activity helps asthma control, but these results suggest it also can impact a patient’s reliance on ICS.”

Researchers also observed a reduction of -0.02 units in use of long-acting β2-agonists (LABA) in the exercise group compared to an increase of 0.24 units in the control group. The exercise group also reported higher rates of reduced symptoms and improved quality of life than the control group.

Sub-group analysis also found that patients in the exercise group with uncontrolled asthma, patients requiring oral corticosteroids 12 months prior to the study, and obese female patients were more likely to see a 2-step asthma treatment reduction than others in the exercise group or the control group as a whole.

The effects persisted after 12 months without negatively impacting patients’ asthma control. “We didn’t see any significant differences in asthma exacerbations between the two groups,” said Dr. Pitzner-Fabricius. “These findings reinforce that regular aerobic exercise is an important tool in asthma management.”

You can learn more about asthma here.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. The AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

“With Diabetes for Dummies 6th edition as your guide, you’ll be empowered to maintain optimal health and truly thrive despite your diagnosis,” say authors Dr. Simon Poole and Amy Riolo.

WASHINGTON (PRWEB)
May 31, 2023

Renowned authors and Culinary Medicine duo Dr. Simon Poole and Chef Amy Riolo are proud to announce their latest release during Mediterranean Diet Month, since the world’s healthiest diet is suited for those looking to avoid, manage, or transform diabetes. According to the American Diabetes Association, 1.4 million Americans are diagnosed with diabetes each year. In 2019, 37.3 million Americans, or 11.3 percent of the population, had diabetes. Many nations around the world aren’t far behind. If you’re living with pre-diabetes, type 1 or type 2 diabetes, you’re not alone. Diabetes For Dummies i s a trusted guide as you navigate this chronic condition (or help a loved one).

This book covers the latest advances in diabetes management including medications, monitoring, self-testing, surgery, and updated nutritional guidelines. Enjoy easy to implement eating plans complete with delicious, chef-driven recipes and exercise advice that will enrich your life. Inside this newly updated and expanded volume you’ll learn the latest in glucose levels, preventing complications, how to enjoy preparing mouthwatering meals that will help keep you looking and feeling your best, new treatment options, as well as how to manage diabetes in children, while pregnant, and as you age. Offering a holistic, person-centered approach, Diabetes For Dummies 6th edition reveals make reversal and remission a reality. In addition, this book helps you, or those you love, achieve the life you want while managing diabetes with lifestyle changes, alternative therapies and the latest medications.

Learn to tackle your symptoms with the confidence that you’re doing the latest stuff and following the newest advances in diabetes treatment. Powerful lifestyle strategies, new medications, monitoring equipment, nutritional guidelines, delicious recipes, and insulin delivery methods―it’s all in this friendly Dummies guide.

• 
  Understand the types of diabetes and learn about your diagnosis
• Learn the latest treatment options, medications, and evidence-based therapies
• Manage your symptoms and live a full life with expert diet and lifestyle tips
• Answer your questions with this trusted, compassionate guide, now in its 6th edition
• Take control and understand how to improve or even prevent and reverse pre-diabetes and diabetes

This book is an indispensable resource for those newly diagnosed with diabetes, and pre-diabetes, their loved ones, and care givers, as well as health care professionals who need an up-to-date reference on the latest in diabetes research.

About Dr. Simon Poole and Chef Amy Riolo

With more than 30 years of expertise in medical field, Dr. Simon Poole, MBBS DRCOG FBMA MIANE is a primary care physician and author based in Cambridge, England with a particular interest in lifestyle medicine and nutrition as well as the management of long-term medical conditions. Best-selling author of 13 books, Amy Riolo is also an award-winning chef, television host, and Mediterranean lifestyle ambassador. Together, Dr. Simon Poole and Chef Amy Riolo share a common passion to promote the world’s #1 diet to help people achieve optimal health. As diabetes experts and authors of the #1 best -selling diabetes book (The Mediterranean Diabetes Cookbook) with American Diabetes Association as well as the #1 new release in category (Diabetes For Dummies 6th edition) and many other books, the culinary medicine duo teach how healthful lifestyle components can powerfully and positively influence well-being by preventing and transforming illness.

Share article on social media or email: